Clinical Trial Update: Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating decitabine with sequential rapamycin or ribavirin in high-risk acute myeloid leukemia completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)
• Rapamycin (sirolimus)
• Ribavirin (ribavirin)

Snippet

Sponsor: University of Rochester | Conditions: Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-07-05